Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Breast Cancer

Free Subscription Articles published in Oncol Rep Retrieve available abstracts of 50 articles: HTML format

Single Articles

July 2024
1. YAO J, Xu T, Tian T, Fu X, et al
   [Retracted] Tripartite motif 16 suppresses breast cancer stem cell properties through regulation of Gli?1 degradation via the ubiquitin?proteasome pathway.
   Oncol Rep. 2024;52:89.
   PubMed     Abstract available
   
   
   March 2024
2. LEI S, Li S, Xiao W, Jiang Q, et al
   [Corrigendum] Azurocidin 1 inhibits the aberrant proliferation of triple?negative breast cancer through the regulation of pyroptosis.
   Oncol Rep. 2024;51:49.
   PubMed     Abstract available
   
   
   
3. YU H, Bian Q, Wang X, Wang X, et al
   Bone marrow stromal cell antigen 2: Tumor biology, signaling pathway and therapeutic targeting (Review).
   Oncol Rep. 2024;51:45.
   PubMed     Abstract available
   
   
   February 2024
4. IRAGAVARAPU-CHARYULU V, Shakya R, Robinson P, Guzman E, et al
   A novel treatment to enhance survival for end stage triple negative breast cancer using repurposed veterinary anthelmintics combined with gut?supporting/immune enhancing molecules.
   Oncol Rep. 2024;51:31.
   PubMed     Abstract available
   
   
   January 2024
5. CHOI S, An HJ, Yeo HJ, Sung MJ, et al
   MicroRNA?606 inhibits the growth and metastasis of triple?negative breast cancer by targeting Stanniocalcin 1.
   Oncol Rep. 2024;51:2.
   PubMed     Abstract available
   
   
   
6. URBAN L, Novak S, Coma M, Dvorankova B, et al
   Unravelling heterogeneous effects of cancer?associated fibroblasts on poor prognosis markers in breast cancer EM?G3 cell line: In vitro?targeted treatment (anti?IL-6, anti?VEGF-A, anti?MFGE8) based on transcriptomic profiling.
   Oncol Rep. 2024;51:3.
   PubMed     Abstract available
   
   
   
7. NANAMIYA T, Takane K, Yamaguchi K, Okawara Y, et al
   Expression of PVRL4, a molecular target for cancer treatment, is transcriptionally regulated by FOS.
   Oncol Rep. 2024;51:17.
   PubMed     Abstract available
   
   
   November 2023
8. YANG K, Wang JQ, Li K, Chen SN, et al
   Pseudolaric acid B induces apoptosis associated with the mitochondrial and PI3K/AKT/mTOR pathways in triple?negative breast cancer.
   Oncol Rep. 2023;50:193.
   PubMed     Abstract available
   
   
   
9. KWON S, Han SJ, Kim KS
   Differential response of MDA?MB?231 breast cancer and MCF10A normal breast cells to cytoskeletal disruption.
   Oncol Rep. 2023;50:200.
   PubMed     Abstract available
   
   
   October 2023
10. LIU C, Liu Z, Li X, Tang X, et al
    [Retracted] MicroRNA‑1297 contributes to tumor growth of human breast cancer by targeting PTEN/PI3K/AKT signaling.
    Oncol Rep. 2023;50:180.
    PubMed     Abstract available
    
    
    
11. LEI S, Li S, Xiao W, Jiang Q, et al
    Azurocidin 1 inhibits the aberrant proliferation of triple?negative breast cancer through the regulation of pyroptosis.
    Oncol Rep. 2023;50:188.
    PubMed     Abstract available
    
    
    September 2023
12. LIU B, Liu H, Liu M
    Aggressive local therapy for de novo metastatic breast cancer: Challenges and updates (Review).
    Oncol Rep. 2023;50:163.
    PubMed     Abstract available
    
    
    August 2023
13. YAMAMOTO Y, Hayashi Y, Sakaki H, Murakami I, et al
    Downregulation of fascin induces collective cell migration in triple‑negative breast cancer.
    Oncol Rep. 2023;50:150.
    PubMed     Abstract available
    
    
    
14. HU H, Wang ZW, Hu S, Xiang Y, et al
    GNPNAT1 promotes the stemness of breast cancer and serves as a potential prognostic biomarker.
    Oncol Rep. 2023;50:157.
    PubMed     Abstract available
    
    
    July 2023
15. NASULEWICZ-GOLDEMAN A, Goldeman W, Papiernik D, Nowak M, et al
    Anti‑metastatic activity of aromatic aminomethylidenebisphosphonates in a mouse model of 4T1 cell‑derived breast cancer.
    Oncol Rep. 2023;50:135.
    PubMed     Abstract available
    
    
    May 2023
16. KAMIYA S, Nakamori Y, Takasawa A, Takasawa K, et al
    Suppression of the vitamin D metabolizing enzyme CYP24A1 provides increased sensitivity to chemotherapeutic drugs in breast cancer.
    Oncol Rep. 2023;49:85.
    PubMed     Abstract available
    
    
    
17. BUTTI R, Kapse P, Bhadauriya G, Ahmad S, et al
    Development and characterization of a patient‑derived orthotopic xenograft of therapy‑resistant breast cancer.
    Oncol Rep. 2023;49:99.
    PubMed     Abstract available
    
    
    
18. LIRA MC, Rosa FD, Aiello I, Machado MS, et al
    NCoA3 upregulation in breast cancer‑associated adipocytes elicits an inflammatory profile.
    Oncol Rep. 2023;49:105.
    PubMed     Abstract available
    
    
    April 2023
19. PAN C, Shao S, Gu Y, Ni Q, et al
    Radiation prevents tumor progression by inhibiting the miR‑93‑5p/EphA4/NF‑kappaB pathway in triple‑negative breast cancer.
    Oncol Rep. 2023;49:78.
    PubMed     Abstract available
    
    
    March 2023
20. HAN S, Jin X, Hu T, Chi F, et al
    LAPTM5 regulated by FOXP3 promotes the malignant phenotypes of breast cancer through activating the Wnt/beta‑catenin pathway.
    Oncol Rep. 2023;49:60.
    PubMed     Abstract available
    
    
    February 2023
21. VELEZ BC, Petrella CP, DiSalvo KH, Cheng K, et al
    Combined inhibition of ACLY and CDK4/6 reduces cancer cell growth and invasion.
    Oncol Rep. 2023;49:32.
    PubMed     Abstract available
    
    
    
22. LIM JS, Kyung SY, Jeon Y, Kim IS, et al
    Anticancer effects of the HDAC inhibitor, 3beta,6beta‑dihydroxyurs‑12‑en‑27‑oic acid, in MCF‑7 breast cancer cells via the inhibition of Akt/mTOR pathways.
    Oncol Rep. 2023;49:43.
    PubMed     Abstract available
    
    
    January 2023
23. BONTEMPS I, Lallemand C, Biard D, Dechamps N, et al
    Loss of CD24 promotes radiation and chemoresistance by inducing stemness properties associated with a hybrid E/M state in breast cancer cells.
    Oncol Rep. 2023;49.
    PubMed     Abstract available
    
    
    November 2022
24. ARMANDO R, Cabrera M, Vilarullo R, Chinestrad P, et al
    In vitro characterization and rational analog design of a novel inhibitor of telomerase assembly in MDA MB 231 breast cancer cell line.
    Oncol Rep. 2022;48.
    PubMed     Abstract available
    
    
    
25. JIANG H, Li X, Wang W, Hu Y, et al
    MYCL promotes the progression of triplenegative breast cancer by activating the JAK/STAT3 pathway.
    Oncol Rep. 2022;48.
    PubMed     Abstract available
    
    
    October 2022
26. HU H, Xiang Y, Zhang XY, Deng Y, et al
    CDCA5 promotes the progression of breast cancer and serves as a potential prognostic biomarker.
    Oncol Rep. 2022;48.
    PubMed     Abstract available
    
    
    September 2022
27. ZHUANG Y, Li X, Zhan P, Pi G, et al
    HIF1alpha and MBP1 are associated with the progression of breast cancer cells by repressing betacatenin transcription.
    Oncol Rep. 2022;48.
    PubMed     Abstract available
    
    
    July 2022
28. SUI Y, Zhang X, Yang H, Wei W, et al
    [Retracted] MicroRNA133a acts as a tumour suppressor in breast cancer through targeting LASP1.
    Oncol Rep. 2022;48.
    PubMed     Abstract available
    
    
    
29. JIRAPONGWATTANA N, Thongchot S, Chiraphapphaiboon W, Chieochansin T, et al
    Mesothelinspecific T cell cytotoxicity against triple negative breast cancer is enhanced by 40s ribosomal protein subunit 3treated selfdifferentiated dendritic cells.
    Oncol Rep. 2022;48.
    PubMed     Abstract available
    
    
    
30. HAM A, Cho MH, Won HS, Jo J, et al
    betacatenin blockers enhance the effect of CDK4/6 inhibitors on stemness and proliferation suppression in endocrineresistant breast cancer cells.
    Oncol Rep. 2022;48.
    PubMed     Abstract available
    
    
    June 2022
31. JIANG Q, He M, Ma MT, Wu HZ, et al
    [Corrigendum] MicroRNA-148a inhibits breast cancer migration and invasion by directly targeting WNT-1.
    Oncol Rep. 2022;47.
    PubMed     Abstract available
    
    
    
32. LI J, Liu L, Chen Y, Wu M, et al
    Ribosome assembly factor PNO1 is associated with progression and promotes tumorigenesis in triplenegative breast cancer.
    Oncol Rep. 2022;47.
    PubMed     Abstract available
    
    
    
33. TAKEDA T, Tsubaki M, Matsuda T, Kimura A, et al
    EGFR inhibition reverses epithelialmesenchymal transition, and decreases tamoxifen resistance via Snail and Twist downregulation in breast cancer cells.
    Oncol Rep. 2022;47.
    PubMed     Abstract available
    
    
    May 2022
34. TSAO AN, Chuang YS, Lin YC, Su Y, et al
    Dinaciclib inhibits the stemness of two subtypes of human breast cancer cells by targeting the FoxM1 and Hedgehog signaling pathway.
    Oncol Rep. 2022;47.
    PubMed     Abstract available
    
    
    March 2022
35. ZHANG H, Wei N, Zhang W, Shen L, et al
    [Retracted] lncRNA SNHG3 promotes breast cancer progression by acting as a miR326 sponge.
    Oncol Rep. 2022;47.
    PubMed     Abstract available
    
    
    
36. CHEN Y, Wei L, Zhang X, Liu X, et al
    [Corrigendum] 3Bromopyruvate sensitizes human breast cancer cells to TRAILinduced apoptosis via the phosphorylated AMPKmediated upregulation of DR5.
    Oncol Rep. 2022;47.
    PubMed     Abstract available
    
    
    February 2022
37. CAO W, Shen R, Richard S, Liu Y, et al
    Inhibition of triplenegative breast cancer proliferation and motility by reactivating p53 and inhibiting overactivated Akt.
    Oncol Rep. 2022;47.
    PubMed     Abstract available
    
    
    January 2022
38. INAISHI T, Shibata M, Ichikawa T, Kanda M, et al
    Platelet isoform of phosphofructokinase accelerates malignant features in breast cancer.
    Oncol Rep. 2022;47.
    PubMed     Abstract available
    
    
    
39. TORNROOS R, Tina E, Gothlin Eremo A
    SLC7A5 is linked to increased expression of genes related to proliferation and hypoxia in estrogenreceptorpositive breast cancer.
    Oncol Rep. 2022;47.
    PubMed     Abstract available
    
    
    December 2021
40. KIM JM, Park J, Noh EM, Song HK, et al
    Downregulation of matriptase suppresses the PAR2/PLCgamma2/PKCmediated invasion and migration abilities of MCF7 breast cancer cells.
    Oncol Rep. 2021;46.
    PubMed     Abstract available
    
    
    
41. THONGCHOT S, Jamjuntra P, Prasopsiri J, Thuwajit P, et al
    Establishment and characterization of novel highly aggressive HER2positive and triplenegative breast cancer cell lines.
    Oncol Rep. 2021;46.
    PubMed     Abstract available
    
    
    November 2021
42. JEON SM, Lim JS, Park SH, Lee JH, et al
    Wnt signaling promotes tumor development in part through phosphofructokinase 1 platelet isoform upregulation.
    Oncol Rep. 2021;46.
    PubMed     Abstract available
    
    
    July 2021
43. CHIU YJ, Tsai FJ, Bau DT, Chang LC, et al
    Nextgeneration sequencing analysis reveals that MTH3, a novel curcuminoid derivative, suppresses the invasion of MDAMB231 triplenegative breast adenocarcinoma cells.
    Oncol Rep. 2021;46.
    PubMed     Abstract available
    
    
    May 2021
44. TREMANTE E, Sibilio L, Centola F, Knutti N, et al
    TOOLBOX: StrepTagged nanoassemblies of antibodydrugconjugates (ADC) for modular and conditional cancer drugging
    Oncol Rep. 2021;45.
    PubMed     Abstract available
    
    
    April 2021
45. CALAF GM, Bleak TC, Roy D
    Signs of carcinogenicity induced by parathion, malathion, and estrogen in human breast epithelial cells (Review).
    Oncol Rep. 2021;45.
    PubMed     Abstract available
    
    
    March 2021
46. XU X, Liu M, Yang Y, Wei C, et al
    VSP‑17 suppresses the migration and invasion of triple‑negative breast cancer cells through inhibition of the EMT process via the PPARgamma/AMPK signaling pathway.
    Oncol Rep. 2021;45:975-986.
    PubMed     Abstract available
    
    
    
47. AN SQ, He K, Liu F, Ding QS, et al
    Low microRNA150 expression is associated with activated carcinogenic pathways and a poor prognosis in patients with breast cancer.
    Oncol Rep. 2021;45:1235-1248.
    PubMed     Abstract available
    
    
    
48. CHEN H, Sun Y, Yang Z, Yin S, et al
    Metabolic heterogeneity and immunocompetence of infiltrating immune cells in the breast cancer microenvironment (Review).
    Oncol Rep. 2021;45:846-856.
    PubMed     Abstract available
    
    
    
49. NAKANISHI M, Korechika A, Yamakawa H, Kawabe N, et al
    Acidic microenvironment induction of interleukin-8 expression and matrix metalloproteinase-2/-9 activation via acid-sensing ion channel 1 promotes breast cancer cell progression.
    Oncol Rep. 2021;45:1284-1294.
    PubMed     Abstract available
    
    
    February 2021
50. LU N, Zhang M, Lu L, Liu YZ, et al
    miRNA4903p promotes the metastatic progression of invasive ductal carcinoma.
    Oncol Rep. 2021;45:706-716.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.